一种胞嘧啶核苷衍生物在制备预防和 / 或治疗埃博拉病毒感染的药物中的用途

By developing cytosine nucleoside derivatives as oral drugs, the problem of the lack of effective oral drugs for treating Ebola virus in existing technologies has been solved. Significant inhibitory activity and low cytotoxicity against Ebola virus have been achieved, making it suitable for widespread application.

CN122398841APending Publication Date: 2026-07-17PLAIN LAB +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
PLAIN LAB
Filing Date
2026-05-29
Publication Date
2026-07-17

Smart Images

  • Figure CN122398841A_ABST
    Figure CN122398841A_ABST
Patent Text Reader

Abstract

本发明提供了一种胞嘧啶核苷衍生物或其药学上可接受的盐在制备预防和 / 或治疗埃博拉病毒感染的药物中的用途，所述胞嘧啶核苷衍生物的结构式如下式（I）所示。本发明挖掘了“老药”的新潜力，将原本用于治疗艾滋病毒和新冠病毒感染而开发的口服药物阿兹夫定（FNC）用于埃博拉病毒的治疗上。目前埃博拉病毒引起的死亡率高达90%，针对该疾病目前还没有有效的治疗药物。因此研究针对埃博拉病毒的药物迫在眉睫。实验结果显示，FNC具有很好的抑制埃博拉病毒的活性和较低的细胞毒性，并且其对埃博拉病毒的抑制活性显著优于对艾滋病毒和新冠病毒的抑制活性。本发明将老药新用，为埃博拉病毒治疗提供了更直接的解决方案，对疫情控制或可起到重要作用。（I）
Need to check novelty before this filing date? Find Prior Art